From GlobeNewswire:

Y-mAbs Therapeutics, Inc. announced it will report financial results for the quarter and full year ending December 31, 2023. The conference call and webcast will take place on February 29, 2024, and March 1, 2024, respectively. You can access the live webcast at the provided link. Y-mAbs is a biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer products.

The company’s technologies include the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. The Company’s product pipeline includes DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with high-risk neuroblastoma after a partial response, minor response, or stable disease to prior therapy. It also has other product candidates and technologies.

During the conference call and webcast, Y-mAbs executives will discuss the Company’s business model, including financial outlook for 2024 and beyond. They will also discuss development, commercialization, product distribution plans, collaborations, and its future financial performance. The company’s common stock, employee matters, and potential challenges in commercializing products such as the rate and degree of market acceptance will also be discussed.

Y-mAbs has registered trademarks for its ground-breaking products, DANYELZA® and Y-mAbs®. For further information, investors can contact Courtney Dugan, VP, Head of Investor Relations at [email protected]. Join the conference call and webcast to gain a better understanding of Y-mAbs’ future plans and projections.



Read more: Y-mAbs to Announce Fourth Quarter and Full Year 2023